Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T ...
Cabaletta Bio, Inc. (Nasdaq: CABA) is a clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, founded in 2017. The company specializes in the development of engineered T cell therapies designed to treat autoimmune diseases where B cells produce harmful autoantibodies. Its proprietary chimeric autoantibody receptor (CAAR) T cell platform aims to ...Cabaletta Bio, Inc. (Nasdaq: CABA) is a clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, founded in 2017. The company specializes in the development of engineered T cell therapies designed to treat autoimmune diseases where B cells produce harmful autoantibodies. Its proprietary chimeric autoantibody receptor (CAAR) T cell platform aims to precisely target and eliminate disease-causing B cells. The lead candidate, DSG3-CAART, is in Phase I clinical trials for mucosal pemphigus vulgaris, a blistering skin disorder, and Hemophilia A patients with Factor VIII alloantibodies. The pipeline also includes MuSK-CAART for myasthenia gravis (preclinical), FVIII-CAART for Hemophilia A (discovery), and DSG3/1-CAART for mucocutaneous pemphigus vulgaris (discovery). The company collaborates with the University of Pennsylvania and the University of California. As of the latest data, it has approximately 154 employees. Financially, Cabaletta Bio has a market cap of around $455 million, a beta of 3.257, and no revenue, typical for a clinical-stage biotech. Key financial metrics show negative profitability, with return on equity of -131.6% and net income per share of -$1.566. The company maintains a strong cash position relative to debt, with a current ratio of 2.947. Leadership includes CEO and Chairman Steven Nichtberger, who co-founded the company with UPenn scientists Michael Milone and Aimee Payne. Cabaletta Bio became public in October 2019 and continues to advance its pipeline toward potential cures for autoimmune diseases.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-167.9M
-44.9%
-17.2%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-132.3M
-46.3%
+2.5%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
24.2%
+136.2%
-52.3%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
2.77x
-55.0%
+96.4%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
